HC Raps Telangana Govt over 18-month Delay in Opening Alampur Hospital

Hyderabad: The Telangana High Court on Friday strongly criticised the state government for its prolonged
inaction in operationalising a fully equipped 100-bed government hospital in Alampur, Jogulamba Gadwal district, despite its completion 18 months ago. 

Also Read:Telangana Medical Council Busts 4 Quacks, Illegal Hospital

The delay, now extending
to 18 months, has drawn the ire of a division bench comprising Acting Chief
Justice Sujoy Paul and Justice Renuka Yara, who demanded a detailed explanation
from the state within two weeks.

The court was hearing a
Public Interest Litigation (PIL) filed by Ramchandra Reddy, a social activist
and political figure from the district. Reddy informed the court that the
hospital was constructed with Rs. 21 crore sanctioned in 2021 and completed by
October 2023. Despite being fully equipped, it has remained unused, with no
staff appointed or medical services initiated. He expressed concern that the
vacant facility is now at risk of being misused by anti-social elements,
reports the TOI.

In his submission, Reddy
emphasised that Alampur, an SC-reserved constituency, is home to a large
population belonging to the Dalit and Backwards Class communities. The failure to
operationalise the hospital, he argued, has forced residents to travel long distances
to access basic healthcare, in violation of their fundamental right to health
under Article 21 of the Constitution.

According to the TOI news report, the bench echoed these
concerns, with Justice Sujoy Paul remarking that the government’s failure to
put the hospital to use not only renders the expenditure wasteful but also
deprives a vulnerable population of essential medical care. The judges directed
the state and the concerned departments to file a counter-affidavit explaining
the delay and outlining the timeline for operationalising the facility. The
matter will be taken up for further hearing once the government submits its
response.

Also Read:3 New TIMS Hospitals to open in Hyderabad by 2025: Minister Komatireddy Venkat Reddy

Medical
Dialogues had earlier reported that in a move to enhance healthcare infrastructure in
Hyderabad, Telangana’s Roads and Buildings Minister, Komatireddy Venkat Reddy,
announced that three new hospitals under the Telangana
Institute of Medical Sciences (TIMS) will begin operations by the end
of 2025. These hospitals, set to be located in Sanathnagar, LB Nagar, and
Alwal, are aimed at reducing the burden on the city’s current public healthcare
facilities.

Powered by WPeMatico

Household Clustering of Hypertension and Diabetes Drives India’s NCD Burden, Finds NFHS-5 Study

India: A recent study led by Sarang Pradipkumar Pedgaonkar from the Department of Family and Generations at the International Institute for Population Sciences in Mumbai sheds new light on how hypertension and diabetes tend to cluster within Indian households. The study, published in PLOS Global Public Health, used nationally representative data to explore this growing public health concern.

While India has seen a rising prevalence of non-communicable diseases (NCDs) like hypertension and diabetes, little was known about how these conditions might affect multiple members within the same household. This research aimed to fill that gap by analyzing data from the fifth round of the National Family Health Survey (NFHS-5, 2019–21), covering individuals aged 15 years and older across all 707 Indian districts. In this context, “clustering” was defined as having two or more household members diagnosed with the same condition.

The following were the key findings of the study:

  • 14.9% of Indian households exhibited clustering of hypertension, contributing to about 50% of the country’s total hypertension cases.
  • 7.7% of households showed clustering of diabetes, accounting for nearly 39.3% of total diabetes cases.
  • Clustering was more common in wealthier, urban households.
  • Households with a larger number of older members or individuals who were overweight or obese had higher clustering rates.
  • Higher consumption of fried foods and fish was associated with an increased likelihood of clustering.
  • Multi-level analysis indicated that community-level factors had the strongest influence on clustering.
  • Certain districts demonstrated particularly high levels of clustering, highlighting the need for targeted and district-specific interventions.

Despite the study’s robust dataset, there were some limitations. Diabetes diagnosis relies on random blood glucose measurements, which are less reliable than HbA1c or fasting blood glucose levels. Additionally, BMI data were only available for women, and dietary intake information was self-reported, potentially introducing recall bias.

Still, the study’s results carry significant implications for India’s health policies. The authors stress the value of household-focused screening and management interventions to improve the detection and treatment of these NCDs. Such strategies could be critical for advancing toward Sustainable Development Goal (SDG) 3.4, which focuses on reducing premature mortality from NCDs.

Furthermore, the research team recommends improvements to future NFHS surveys, including the collection of more comprehensive data on diet, physical activity, and the timing of disease onset. The study also offers a model for other low- and middle-income countries to better understand how NCDs cluster within families and communities.

The authors concluded, “By identifying key risk factors and regional patterns, this work provides actionable insights for more effective public health interventions and policy design aimed at tackling the growing burden of hypertension and diabetes in India.”

Reference:

Pedgaonkar SP, Kumar K, Meitei WB, Kumar S, Upadhyay AK, Maurer J, et al. (2025) Clustering of hypertension and clustering of diabetes within households across districts of India: A cross-sectional analysis using a nationally representative household survey. PLOS Glob Public Health 5(6): e0004648. https://doi.org/10.1371/journal.pgph.0004648

Powered by WPeMatico

Lifestyle Interventions show promise for promoting Cardiometabolic Health in Black American Women of childbearing age: Study

Cardiometabolic disorders among childbearing women, particularly within the Black American demographic, significantly contribute to detrimental perinatal outcomes and long-term health effects. Existing literature suggests that lifestyle interventions, such as health education and lifestyle counseling, are vital for enhancing cardiometabolic health, yet there is scarce research specifically targeting this population. Recently published article suggests that there is a significant lack of research focused on lifestyle interventions before pregnancy that target the enhancement of cardiometabolic health.

Prevalence of Conditions

The prevalence of conditions such as diabetes and hypertension is notably higher in Black American women compared to their non-Hispanic White counterparts. Contributing factors include environmental and structural influences as well as behavioral risk factors like physical inactivity and poor dietary habits. Addressing these issues is crucial for improving maternal and neonatal health.

Focus on Health Education

Many of the reviewed studies focus predominantly on health education, emphasizing physical activity and nutrition while often neglecting psychosocial health, which is critical for comprehensive wellbeing. The findings also indicate that a majority of the studies employed similar delivery methods for interventions, such as group education and in-person counseling, though there was limited integration of advanced digital health technologies like mobile applications or social media platforms.

Research Gaps

Furthermore, the review highlighted a significant gap in research concerning pre-pregnancy lifestyle interventions aimed at enhancing cardiometabolic health, despite evidence indicating that improved health in this phase can reduce adverse outcomes. Notably, the need for culturally appropriate interventions is underscored, employing frameworks that consider the multifaceted factors affecting health equity.

Challenges in Existing Studies

While some studies demonstrated improvements in health behaviors, such as increased physical activity and healthier dietary choices, evidence related to substantial cardiometabolic outcomes remains limited. High attrition rates, small sample sizes, and challenges related to participant engagement were common issues among the included studies, indicating a need for improved methodologies.

Future Research Directions

Integrating technology to enhance participant engagement and adopting flexible delivery methods could increase accessibility to these interventions. Future research should aim for larger, more diverse populations and methodological rigor. Overall, establishing effective lifestyle interventions tailored for Black American women of childbearing age is essential to address and reduce health disparities, ultimately fostering healthier maternal and neonatal outcomes. More robust, culturally responsive strategies could significantly improve the cardiometabolic health and wellbeing of this high-risk group.

Key Points

– Cardiometabolic disorders are prevalent among Black American women, contributing to poor perinatal outcomes and long-term health effects. The heightened prevalence of diabetes and hypertension in this demographic necessitates targeted health interventions.

– Environmental, structural, and behavioral factors, such as physical inactivity and poor dietary habits, are significant contributors to the higher rates of cardiometabolic conditions, highlighting the importance of addressing these issues for better maternal and neonatal health.

– Existing studies predominantly emphasize health education focusing on physical activity and nutrition, while underrepresenting psychosocial health aspects. Furthermore, most interventions utilized conventional delivery methods, with a lack of integration of modern digital health technologies.

– A notable research gap exists regarding pre-pregnancy lifestyle interventions aimed at improving cardiometabolic health, despite evidence indicating that health improvements during this phase can lead to reduced adverse outcomes.

– Challenges in current research include high attrition rates, small sample sizes, and difficulties with participant engagement, which affect the validity of findings related to cardiometabolic outcomes. These methodological issues highlight the need for improved research designs.

– Future research must prioritize the integration of technology to enhance participant engagement, adopt flexible intervention delivery methods, and focus on larger, more diverse populations. Culturally responsive lifestyle interventions are crucial for improving cardiometabolic health and reducing disparities among Black American women of childbearing age.

Reference –

E. Owolabi et al. (2025). Lifestyle Interventions Addressing Cardiometabolic Health Among Black American Women Of Reproductive Age In The U.S. : An Integrative Review. *BMC Pregnancy And Childbirth*, 25. https://doi.org/10.1186/s12884-025-07490-7

Powered by WPeMatico

Preeclampsia Predicament: Study Forecasts Risks from Gestational Day One

Recently published study focused on the challenges of predicting preeclampsia (PE) within the first 16 weeks of gestation due to its complex nature, poorly understood causes, and multiple pathogenic phenotypes. PE is characterized by hypertension after 20 weeks of gestation and related complications affecting maternal and fetal health. Despite advancements in understanding PE, predicting it early remains difficult due to various risk factors and different phenotypes of the condition.

Multi-Omics Approach in Predictive Modeling

The research employed a multi-omics approach, analyzing proteomic and metabolomic data alongside clinical and laboratory information to develop predictive models for EPE and LPE. By utilizing machine learning algorithms like the Boruta algorithm and random forest models, the study identified sets of metabolites and proteins predictive of PE. Notably, certain metabolites such as L-Malic acid and proteins like Superoxide dismutase 3 were found to be associated with PE. Different combinations of clinical factors, omics biomarkers, and laboratory test results were integrated into the predictive models to enhance accuracy. The models proved effective in distinguishing EPE and LPE patients from healthy controls, showcasing superior performance compared to models solely based on clinical factors or single omics data. The addition of laboratory test variables further improved prediction accuracies early in pregnancy.

Identification of Potential Biomarkers for PE

The study highlighted metabolites related to pathways like arginine biosynthesis and proteins involved in immune responses and oxygen transport as potential biomarkers for PE. Integrating clinical, omics, and laboratory data offered novel approaches to predict PE in early pregnancy, providing valuable insights for timely intervention and management. Although the study demonstrated promising results, certain limitations like a small sample size and focusing on a specific cohort were acknowledged. Generalizability to other populations and the interpretation of identified biomarkers require further investigation. Future studies will aim to validate the developed models with larger cohorts and explore the functional implications and molecular mechanisms underlying the identified biomarkers for better understanding and management of PE.

Key Points

– Preeclampsia (PE) is a complex condition characterized by hypertension and related complications affecting maternal and fetal health after 20 weeks of gestation.

– Despite advancements in understanding PE, early prediction remains challenging due to its multifactorial nature, poorly understood causes, and different pathogenic phenotypes.

– A multi-omics approach, combining proteomic and metabolomic data with clinical and laboratory information, was used to develop predictive models for early-onset (EPE) and late-onset (LPE) preeclampsia.

– Machine learning algorithms such as the Boruta algorithm and random forest models identified specific metabolites (e.g., L-Malic acid) and proteins (e.g., Superoxide dismutase 3) associated with PE. – Integrated predictive models that included clinical factors, omics biomarkers, and laboratory test results showed superior performance in distinguishing EPE and LPE patients from healthy controls compared to models based solely on clinical factors or single omics data.

– Metabolites related to pathways like arginine biosynthesis and proteins involved in immune responses and oxygen transport were highlighted as potential biomarkers for PE, offering novel approaches for early prediction and management, though further validation with larger cohorts is needed for generalizability and functional implications.

Reference –

Qiang Zhao et al. (2025). Early Prediction Of Preeclampsia From Clinical, Multi-Omics And Laboratory Data Using Random Forest Model. *BMC Pregnancy And Childbirth*, 25. https://doi.org/10.1186/s12884-025-07582-4.

Powered by WPeMatico

Variability in heart rate during sleep may reveal early signs of stroke, depression or cognitive dysfunction, new study shows

New research, presented today at the European Academy of Neurology (EAN) Congress 2025, has uncovered a powerful link between nighttime heart rhythm and future health conditions, even in people with no obvious sleep problems.

The study, which was conducted at the Department of Neurology, Inselspital, the University Hospital of Bern, analysed 4,170 individuals over an observation period of 13,217 person-years, found that heart rate variability (HRV) during sleep can serve as a powerful early warning sign of future health conditions, including stroke, depression, and cognitive dysfunction.

HRV reflects the fluctuation of time intervals between heartbeats. HRV adjusts constantly in response to physical and emotional demands of the body. During the day, HRV is physiologically high corresponding to high levels of activity. At night, and especially during deep sleep, HRV typically reduces, reflecting a shift into a rest and repair mode, where the body focuses on recovery and recharging for the next day.

The research found that certain HRV patterns were linked to future health conditions. Participants who later developed stroke often showed unusually high and erratic HRV. In contrast, low HRV was common in those who further developed depression. High HRV with altered frequency patterns were also observed in individuals who later developed metabolic diseases. Similarly, cardiovascular and endocrine diseases were also associated with high HRV.

“HRV matters for brain and overall health because it reflects how well the body regulates itself – primarily through the activity of the autonomic nervous system”, explained the lead author of the study, Irina Filchenko, MD, PhD. “This system controls vital unconscious processes such as breathing, digestion and muscle tone, helping the body maintain balance and adapt to internal and external demands.”

“While many people are familiar with tracking sleep stages or total sleep time, nocturnal HRV provides a unique window into how the body functions during sleep. This is especially important because sleep is a critical time for many physiological processes underlying long-term health, such as cellular repair, memory consolidation, and the clearance of metabolic waste from the brain.”

Importantly, researchers believe that HRV could act as an early physiological marker, demonstrating subtle changes in body functioning before traditional symptoms or diagnoses appear. This could open the door to prevention and early intervention for diseases like Alzheimer’s or stroke, where timely action can improve patient outcomes.

Dr Filchenko noted, “Some participants had ‘normal’ sleep according to traditional criteria, with little sleep fragmentation and the expected balance of sleep stages. However, HRV told a different story, picking up risks that the common sleep metrics missed. This suggests we need to rethink how we define and measure optimal sleep.”

The findings of the study also raise the possibility of using wearable technology to monitor HRV patterns over time. While current consumer devices vary in accuracy and interpretability, experts believe future improvements could allow people to track changes in HRV as part of regular health monitoring.

The research adds to growing evidence that sleep is a critical pillar of long-term health, and that subtle patterns could offer a window of opportunity to prevent serious disease. “The broader message is that sleep is not just a passive state of rest-it is an active, dynamic process that plays a vital role in maintaining long-term health, especially brain health. Our findings reinforce the idea that primary prevention matters, and that health problems start long before the clinical symptoms appear”, concluded Dr Filchenko.

Reference:

Variability in heart rate during sleep may reveal early signs of stroke, depression or cognitive dysfunction, new study shows, Beyond, Meeting: European Academy of Neurology (EAN) Congress 2025.

Powered by WPeMatico

Study identifies umbilical cord blood biomarkers of early onset sepsis in preterm newborns

Scientists from Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago and colleagues identified several proteins from the umbilical cord blood of preterm newborns that signal acute systemic inflammation as an immune response to infection, providing objective and noninvasive means to diagnose early onset sepsis. This finding could spare infants from prolonged exposure to unnecessary antibiotics, which leaves them at risk for subsequent serious infections and dysregulation of the microbiome that can impact the immune system and metabolism. Results were published in JCI Insight.

Early onset sepsis occurs within 72 hours of life and is more common in preterm infants. It usually develops in utero, and intraamniotic infection is often the trigger for preterm birth. Early onset sepsis is hard to diagnose definitively from clinical signs, so antibiotics are started while waiting for culture results. Among very low birth weight infants nationally, 78 percent receive antibiotics after delivery. Around 25 percent of these babies are continued on antibiotics even when culture results are negative because they are presumed to have sepsis.

“Cord blood is an excellent source of information on the state of the baby’s health at the time of delivery. Cord blood biomarker results can be available within 24 hours, allowing physicians to rule out early onset sepsis and discontinue antibiotics with more confidence,” said lead author Leena B. Mithal, MD, pediatric infectious diseases specialist and Neal, Kathleen, and Adam Kulick Endowed Research Scholar at Lurie Children’s, as well as Associate Professor of Pediatrics at Northwestern University Feinberg School of Medicine. “This could be an important advance in the care of premature infants.”

Dr. Mithal and colleagues also developed a machine learning diagnostic algorithm based on cord blood biomarkers and risk factors for early onset sepsis. This innovation has a patent pending.

“The next step will be to validate our findings through multicenter studies and clinical trials,” said Dr. Mithal.

Reference:

Leena B. Mithal, Mark E. Becker, Cord blood proteomics identifies biomarkers of early-onset neonatal sepsis, JCI Insight, DOI: 10.1172/jci.insight.193826.

Powered by WPeMatico

Real-World Data Shows Insulin Pumps May Cut Deaths, But Raise Retinopathy Risk in Type 1 Diabetes

UK: A large-scale real-world analysis has revealed that insulin pump therapy offers significant survival benefits and lowers the risk of diabetic ketoacidosis (DKA) in adults with type 1 diabetes when compared to multiple daily injections (MDI). The findings were published in Diabetes, Obesity and Metabolism and stem from a retrospective cohort study led by Sophie Haughton and colleagues from Sheffield Teaching Hospitals, UK.

Using data from the TriNetX global health research platform, researchers analyzed medical records of over 95,000 individuals with type 1 diabetes between January 2018 and March 2025. After matching cohorts for key factors such as age, gender, ethnicity, kidney function, and baseline HbA1c, 17,124 patients remained in each group — those using insulin pumps and those on MDI.

The key findings of the study were as follows:

  • Insulin pump users had a 28% lower risk of all-cause mortality over five years compared to those on multiple daily injections (MDI) (RR = 0.72).
  • Pump therapy was associated with a 15% reduction in the risk of diabetic ketoacidosis (DKA) (RR = 0.85).
  • Both groups achieved meaningful improvements in glycemic control, with the pump group showing a slightly greater reduction in HbA1c levels (−5.3 mmol/mol) compared to the MDI group (−4.5 mmol/mol).
  • Insulin pump users demonstrated a 33% increased risk of developing diabetic retinopathy (RR = 1.33).

While the researchers caution against drawing definitive conclusions from this observation, they suggest that differences in retinal screening frequency between the two groups may have contributed to this result, potentially introducing detection bias.

“These results reflect the everyday use of insulin pumps outside of controlled trial settings and offer valuable insights for diabetes care,” the authors noted. “While pump therapy appears to lower mortality and reduce the risk of DKA, the increased incidence of retinopathy needs further investigation, particularly in the context of screening patterns.”

In summary, the real-world study adds important evidence in favor of insulin pump therapy as a potentially superior option for managing type 1 diabetes. The authors suggest that despite the increased risk of retinopathy, the reductions in DKA and mortality present a compelling case for broader use of pump technology, especially in populations at higher risk of complications.

“As healthcare providers weigh treatment strategies for type 1 diabetes, these findings may help inform more personalized and outcome-driven decisions in clinical practice,” the authors concluded.

Reference:

Haughton S, Riley D, Berry S, Arshad MF, Eleftheriadou A, Anson M, Yap YW, Cuthbertson DJ, Malik RA, Azmi S, Alam U, Iqbal A. The impact of insulin pump therapy compared to multiple daily injections on complications and mortality in type 1 diabetes: A real-world retrospective cohort study. Diabetes Obes Metab. 2025 May 19. doi: 10.1111/dom.16455. Epub ahead of print. PMID: 40390300.

Powered by WPeMatico

FMG Internship Extension from 2 to 3 years in MP: High Court Defers hearing to June 23

Bhopal: The plea challenging the extension of the Foreign Medical Graduate (FMG) internship period has been deferred by the Madhya Pradesh High Court.

Altogether, nine medical graduates from abroad had challenged the extension of their mandatory internship period from 2 years to 3 years by the State. Even though the matter was listed for hearing on June 19, 2025, it has now been scheduled for further hearing on June 23, 2025.

According to the existing rules, foreign medical graduates must undergo one year of internship in a medical college of the State after completing their medical education abroad. This is necessary to be able to get a permanent registration to practice medicine in India. During the COVID-19 outbreak, the duration of the internship was increased to two years.

Medical Dialogues had earlier reported that a group of FMGs had filed a plea before the Madhya Pradesh High Court when their internship tenure was extended from 2 to 3 years just before they were going to complete their internship. They claimed that the MP Medical Council increased the duration of their internship by another year when only four months were left to complete the internship. While they were about to complete the internship term in March 2025, they were informed on November 4, 2024, that their internship period would now be for a period of three years.

Also Read: FMG Internship Extension from 2 to 3 years in MP: HC notice to state, NMC, Medical Council

Previously, while considering the plea, the Madhya Pradesh High Court had sought to know the stand of the State Government and the State Medical Council regarding the matter. During the hearing of the case on May 19, a Division bench of the High Court comprising Justices Sanjeev Sachdeva and Vinay Saraf sought clarification from the National Medical Commission (NMC) regarding the reason behind 2 years of clerkship for the FMGs to compensate for their online training.

The petitioners’ counsel had argued before the Court that the NMC circular had been incorrectly been applied to the petitioners and other students who had pursued the medical course in China as the circular was applicable only to those who studied in Ukraine and later it had been clarified to apply the same for the students in Phillippines as well. However, it had no application for the students in China.

Recently, in the order dated May 2, considering the fact that the last date to apply for the NEET PG 2025 examination is 7th May 2025, the Court had allowed them to fill out the NEET PG exam form.

Later, granting interim relief to these medical graduates from abroad, the Madhya Pradesh High Court provisionally allowed them to appear in the National Eligibility-Entrance Test for Postgraduate (NEET-PG) 2025 examination.

Also Read: ‘What’s the Logic Behind 2-Year Clerkship?’: MP HC asks NMC, Allows 9 FMGs to Appear for NEET PG 2025

Powered by WPeMatico

Imbruvica gets positive EMA Committee opinion for untreated mantle cell lymphoma eligible for Stem Cell Transplant: Janssen-Cilag International

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval for an indication extension of IMBRUVICA (ibrutinib) in frontline mantle cell lymphoma (MCL).

Ibrutinib is a once-daily oral medication that is jointly developed and commercialised by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. Ibrutinib blocks the BTK protein, which is needed by normal and abnormal B-cells, including specific cancer cells, to multiply and spread. By blocking BTK, ibrutinib may help move abnormal B-cells out of their nourishing environments and inhibits their proliferation.

The recommendation is for ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (ibrutinib + R-CHOP) alternating with R-DHAP (or R-DHAOx)* without ibrutinib, followed by ibrutinib monotherapy, for the treatment of adult patients with previously untreated MCL who would be eligible for autologous stem cell transplant (ASCT). The extended indication is based on data from the pivotal Phase 3 TRIANGLE study.

“The CHMP recommendation is an important milestone for patients with previously untreated MCL, an aggressive disease which requires complex and challenging treatment,” said Ester in’t Groen, EMEA Therapeutic Area Head Haematology, Johnson & Johnson Innovative Medicine. “We are excited by the innovation that ibrutinib continues to bring and hope to soon offer patients this frontline option that has demonstrated improved overall survival without the burden, toxicity and time in hospital associated to an ASCT-based treatment regimen.”

The CHMP recommendation for ibrutinib is supported by data from the randomised Phase 3 TRIANGLE study, conducted by the European MCL Network ( NCT02858258 ), which evaluated 870 patients across three treatment arms to assess whether the addition of ibrutinib to chemotherapy with or without ASCT could improve outcomes and potentially remove the need for transplant in patients with previously untreated MCL who were suitable for high-dose treatment. The study demonstrated that adding ibrutinib to chemotherapy followed by a 2-year fixed-duration maintenance period instead of ASCT provides significantly longer overall survival and superior failure-free survival compared to the chemotherapy regimen including ASCT.

“At Johnson & Johnson, we are committed to improving outcomes for patients facing complex blood cancers,” said Jessica Vermeulen, Vice President, Lymphoma & Leukemia Disease Area Stronghold Leader, Johnson & Johnson Innovative Medicine. “The TRIANGLE study, conducted by the European MCL Network, affirms the potential emergence of a new standard of care for transplant eligible patients diagnosed with MCL and represents the first major step forward for these patients in many years. We look forward to working together to bring this transplant-free therapeutic option to the MCL community.”

MCL is a rare, aggressive form of non-Hodgkin lymphoma. The current standard of care in the frontline setting for young and fit patients is a chemotherapy regimen including ASCT, which can be associated with severe toxicities, lengthy hospital stays and high health resource utilisation. The addition of fixed-duration ibrutinib to chemotherapy offers the potential for long treatment-free remissions while avoiding the burden of stem cell transplant. If approved, ibrutinib would become the first Bruton’s Tyrosine Kinase inhibitor (BKTi) for frontline treatment of transplant eligible MCL patients.

Ibrutinib is approved in more than 100 countries and has been used to treat more than 325,000 patients worldwide. There are more than 50 company-sponsored clinical trials, including 18 Phase 3 studies, over 11 years evaluating the efficacy and safety of ibrutinib. In October 2021, ibrutinib was added to the World Health Organization’s Model Lists of Essential Medicines (EML), which refers to medicines that address global health priorities and which should be available and affordable for all.

Ibrutinib was first approved by the European Commission (EC) in 2014, and approved indications to date include:

  • As a single agent or in combination with rituximab or obinutuzumab or venetoclax for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL)
  • As a single agent or in combination with bendamustine and rituximab (BR) for the treatment of adult patients with CLL who have received at least one prior therapy
  • As a single agent for the treatment of adult patients with relapsed or refractory MCL
  • As a single agent for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. In combination with rituximab for the treatment of adult patients with WM

Powered by WPeMatico

AIIMS INI CET July 2025 Round 1 results on June 25- Check out seat allocation Guidelines

New Delhi- The All India Institute of Medical Sciences (AIIMS) New Delhi recently released the provisional information brochure for the 1st and 2nd round of online seat allocation (Institute and subject/Speciality)/ process for [MD/MS/DM(6yrs.)/MCH(6yrs.)/MDS] for the July 2025 session.

Through the brochure, the AIIMS New Delhi has detailed the important information for the candidates, such as eligibility, procedure, age limit, etc. The brochure has been released on the official website of AIIMS New Delhi.

Below are the complete details-

Also Read: AIIMS INI CET July 2025 Counselling Schedule Out, 1360 seats available for candidates, Check out FAQs

ELIGIBILITY

All the candidates who have been listed in the Result will be eligible to participate in the 1st and 2nd Round of the Online Seat Allocation, except rank of OBC/EWS candidates lower than the cut-off rank of UR who failed to produce a valid category certificate.

PROCEDURE

1 The eligible candidates will have to Login themselves to the PG Online Seat Allocation portal. The link for the portal will be activated only for eligible candidates in the MyPage and password may be reset by click on “Forgot Password” button and also an email containing link for the online seat allocation Portal and login credentials (Login ID and Password) will be sent to the registered email address of the eligible candidates. To retrieve the login credentials, click on the Forgot your login details button on the Registration/login Page.

2 The PG Online Seat Allocation portal will allow candidates to make choices of seats (a combination of Institute and subject/speciality) as per his/her eligibility. The candidate can arrange the choices in the desired order of preference. There is no limitation on the number of choices (Institute & Subject/Speciality) that can be made by the candidates. The choices can be edited and reordered within the date and time specified in the Important Dates link in the Portal.

3 Kindly note that the choices cannot be edited and reordered after the closing date of exercising of Choice of the 1st Round of seat allocation. The allocation of the 2nd Round will be done as per the choices made by the candidates during the exercise of the Choice of the 1st Round of seat allocation.

4 The Portal will remain open on dates specified in the Important Dates link in the Portal. The choices made by the candidate will be locked either by the candidate OR will be automatically locked on the last Date and Time as specified in the Important Dates link in the Portal.

5 A Mock Seat Allocation will be done prior to the 1st Round of Seat Allocation (not a final allocation). The mock seat allocation represents the likely seat that a candidate may be allocated as per choices made by the candidate. The result of the mock round seat allocation will be announced as per the date specified in the Important Dates link. The candidate can register/edit/reorder their choices before the closing dates of choices for the 1st Round as per the Important Dates link in the Portal.

6 Those who will not login during exercising of choices (Institute and subject/speciality) for First Round their order of choice will be considered as per choices made during Mock Round.

UPPER AGE LIMIT

1 NIMHANS, Bengaluru (As on 1st July 2025): The age validation for Courses of NIMHANS under INI-CET for July 2025 session

For MD Psychiatry Course-

1 General/Unreserved Category’- 32 Years (Candidates Born on or after 01.07.1993 are eligible).

2 ‘OBC Category’- 35 Years (Candidates Born on or after 01.07.1990 are eligible).

3 ‘SC/ST/PWBD Category’-37 Years (Candidates Born on or after 01.07.1988 are eligible).

4 ‘Sponsored Category’- 45 Years (Candidates Born on or after 01.07.1980 are eligible).

DM (Neurology), M.Ch. Neurosurgery (Post MBBS category) Course & MD Physical Medicine & Rehabilitation- 32 Years (Candidates Born on or after 01.07.1993 are eligible).

2 SCTIMST Trivandrum (As on 1 st July 2025): The age validation for Courses of SCTIMST under INI-CET for July 2025 session-

i General/Unreserved/ EWS/Foreign National category- 40 Years (candidates Born on or after 01.07.1985 are eligible).

ii SC/ST/ Ex-service personnel/PwBD – 45 Years (Candidates Born on or after 01.07.1980 are eligible).

iii OBC – 43 Years (Candidates Born on or after 01.07.1982 are eligible).

iv Sponsored– 50 Years (Candidates Born on or after 01.07.1975 are eligible).

INSTITUTE PREFERENCE

1 AIIMS New Delhi & other AIIMS- The allocation of Institute preferences will be done as per Roster Point Allocation for Counselling (Dynamic) which will be announced separately.

2 JIPMER, Puducherry: Allocation of Institute preference for JIPMER Puducherry candidates, seats shall be done as per Roster Point (Dynamic).

3 NIMHANS, Bengaluru: No seat available for Institute Preference.

4 PGIMER, Chandigarh: No seat available for Institute Preference.

5 SCTIMST, Trivandrum: No seat available for Institute Preference.

FOREIGN NATIONAL CANDIDATES

The seat allocation will be done in order of merit and according to choices made by the candidates.

1 The candidates will be eligible to exercise of choice only as per Subject/ Institute those are filled in the online registration form.

2 All allocation of Foreign National candidates will be done on the basis of as per Subject/Institute filled in the online registration for July 2025 session.

3 Only one best Subject/Speciality and Institute available at that rank will be allocated during online seat allocation.

4 The process of admission will be done as per procedure available for other candidates.

SPONSORED CANDIDATES

1 The seat allocation will be done in order of merit and according to choices made by the candidates.

2 In case any discrepancy found in online data with Sponsorship certificate valid information as in Sponsorship certificate will be accepted as per eligibility criteria.

3 The candidates are eligible to exercise of choice only as per Subject/ Institute those are available in the Sponsorship Certificate.

4 In case, the NOC has been received in place of Sponsorship certificate, the seat allocation will be done as per subject/Institute available in the online registration.

5 If the subject is not mentioned against the candidate name in the Sponsorship certificate, no allocation will be done for that institute.

6 If the subject is not mentioned against the candidate name in the Sponsorship certificate, but subject is available in the online registration, the candidate can make exercising of choices as per subject available in the online registration.

7 All allocation of Sponsored candidates will be done on the basis of Subject/Institute available in the Sponsorship Certificate/online registration for July 2025 session.

8 Only one best Subject/Speciality and Institute available at that rank will be allocated during online seat allocation.

9 The process of admission will be done as per procedure available for other candidates.

ONLINE PG SEAT ALLOCATION PROCESS

Only the eligible candidates will be able to exercise their choices (Institute and subject/speciality) for online PG Seat allocation except rank of OBC/EWS candidates lower than the cut off rank of UR who failed to produce valid category certificate.

The eligible candidates will have to Login themselves on PG Online Seat Allocation portal. The link for the portal will be activated only for eligible candidates in the MyPage and password may be reset by click on “Forgot Password” button and also an email containing link for the online seat allocation Portal and login credentials (Login ID and Password) will be sent to the registered email address of the eligible candidates.

To retrieve the login credentials, click on the Forgot your login details button in the Registration/login Page.

REGISTRATION FOR THE ONLINE PG SEAT ALLOCATION PROCESS

An email containing link for the online seat allocation Portal and login credentials (Login ID and Password) will be sent to the registered email address of the eligible candidates. Further candidate can also login through their MyPage on clicking the link for online seat allocation, the eligible candidates will be directed to online PG Seat allocation portal where the candidates will have to login by click on “Forgot Password” button for online seat allocation. This password is only to access the online PG Seat allocation portal.

The candidate will be able to login to the online PG Seat allocation portal and begin the process of making choices (Institute and subject/speciality) and order the choices. The online PG Seat allocation portal will be remained open for date and time specified in the Important Dates link.

MAKING CHOICES

The choices can only be made after you have registered and logged in using the new password for this portal. On logging in, confirm your name and candidate ID. Click on Make Choice button to proceed to exercise choices (Institute and subject/speciality) and their order. To add a choice, choose the Institute and the subject/speciality from the two separate drop-down menus and Click Add choice. To remove a choice, click on Delete button against that Choice (Institute and subject/speciality). Click on the Save button to save the choices of Institute and subject/speciality and their order.

The default order of your choices (Institute and subject/speciality) will be the order in which you add choice (Institute and subject/speciality). To reorder your choices, use up and down arrows OR Drag and Drop the choice (Institute and subject/speciality) to appropriate position in the list.

Candidates can make choices (Institute and subject/speciality), edit or reorder them as many times they wish UNLESS they have already submitted and locked the choices (Institute and subject/speciality) OR last date and time 1 st Round is over. The candidate must save the choices (Institute and subject/speciality) in case they wish to add/delete/reorder them at a later time point (before the last date and time for 1 st Round).

SUBMITTING AND LOCKING CHOICES

The candidate should click on the Submit and Lock Choices tab and tick the check box ‘I accept the declaration’ and click on the submit and Lock choices (Institute and subject/speciality). Note that it will be prompted twice to reconsider and after it have been submitted and locked the choices (Institute and subject/speciality), it cannot change it for further Rounds.

In case the candidate has made and saved choices but could not submit and Lock choices, the last saved choices (Institute and subject/speciality) and their order will be automatically considered as submitted and locked choices (Institute and subject/speciality).

VIEWING AND PRINTING THE CHOICES AFTER SUBMISSION

The candidate can view the choices submitted and locked by them by clicking on the View choices button after logging in the online PG Seat allocation portal. Click Print button to take a printout. In case of any discrepancy please send a query to the Assistant Controller (Examinations) Through the help/query section of choice making dashboard.

Medical Dialogues has recently reported regarding the schedule of Online Seat Allocation for admission to Postgraduate (PG) courses of INIs [MD/MS/DM(6yrs.)/MCH(6yrs.)/MDS] INI-CET for the July 2025 session.

Below is the complete schedule-

SCHEDULE FOR 1ST ROUND OF ONLINE SEAT ALLOCATION (INCLUDING MOCK ROUND)

S.NO

PARTICULARS

DATE, DAY & TIME

1

Exercising of Choices (Institute and subject/speciality) for Mock Round.

14 June 2025 (Saturday) to 17 June 2025 up to 05.00 pm (Tuesday)

2

Announcement of Seat Allocation of Mock of 1st Round.

18 June 2025 (Wednesday)

3

Exercising of Choices (Institute and subject/speciality) for First Round.

18 June 2025 (Wednesday) to 20 June 2025 up to 05:00 PM (Friday)

4

Announcement of seat allocation of 1st Round.

25 June 2025 (Wednesday)

5

Online Acceptance of the allocated seat.

26 June 2025, 11.00 am (Thursday) to 30 June 2025 up to 05.00 pm (Monday)

6

Reporting & Submission of Documents/Security Deposit.

26 June 2025, 11.00 am (Thursday) to 30 June 2025, up to 05.00 pm (Monday)

SCHEDULE FOR 2ND ROUND OF ONLINE SEAT ALLOCATION

S.NO

PARTICULARS

DATE, DAY & TIME

1

Announcement of Seat Allocation of 2nd Round.

10 July 2025 (Thursday)

2

Online Acceptance of the allocated seat.

11 July 2025, 11.00 am (Friday) to 16 July 2025, up to 05.00 pm (Wednesday)

3

Reporting & Submission of Documents/Security Deposit.

11 July 2025, 11.00 am (Friday) to 16 July 202,5 up to 05.00 pm (Wednesday)

To view the brochure, click the link below

https://medicaldialogues.in/pdf_upload/aiims-ini-cet-july-2025-counselling-know-complete-eligibility-procedure-key-guidelines-for-1st-2nd-round-pg-seat-allocation-290966.pdf

Powered by WPeMatico